Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

AVTX-009 · FL101

Other · developed by Avalo Therapeutics

Phase 2 Most advanced trial (none active)

AVTX Developer

1 Registered trials

What is AVTX-009?

AVTX-009 is an agent given as a subcutaneous injection every 2 or 4 weeks. It is being studied in hidradenitis suppurativa, a chronic inflammatory skin disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: FL101
Drug type: Other
Therapy area: Dermatology
Developer: Avalo Therapeutics, Inc. (AVTX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: FJZ68XPT4U

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06603077	Phase 2	Hidradenitis Suppurativa	Completed	AVTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hidradenitis Suppurativa

More from Avalo Therapeutics

AVTX-002 Phase 2 Camoteskimab Phase 1 CERC-006 Phase 1 CERC-301 Phase 2 FP01 Phase 2

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the AVTX page.

Follow AVTX, the company behind AVTX-009

See AVTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AVTX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z